Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 8/20 | 0.42 |
| ▸ | RAMP1 | O60894 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27778262 | 0.83 | HTR2C (0.51) | MAPTAGTR2HTR2CHTR2BDPP4 | |
| SCHEMBL2675482 | 0.80 | AGTR2 (0.54) | MAPTAGTR2HTR2CHTR2BDPP4 | |
| SCHEMBL2675232 | 0.78 | OPRM1 (0.52) | MAPTAGTR2HTR2CHTR2BOPRM1 | |
| SCHEMBL2087424 | 0.77 | CALCRL (0.55) | CALCRLRAMP1 | |
| SCHEMBL2676323 | 0.76 | AGTR2 (0.49) | MAPTAGTR2HTR2CHTR2BDPP4 | |
| SCHEMBL31285861 | 0.75 | OPRM1 (0.65) | MAPTOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL22588011 | 0.75 | OPRM1 (0.65) | MAPTOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL2103739 | 0.74 | CALCRL (0.58) | CALCRLRAMP1 | |
| SCHEMBL30231301 | 0.74 | CALCRL (0.58) | CALCRLRAMP1 | |
| Oxalic Acid SCHEMBL8173155 | 0.72 | MAPT (0.83) | MAPTCRBNNPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173813-B2 | selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants | NEURAXON, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | MAPT 1956/4885AGTR2 1371/4885CRBN 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.